Possible role of adjuvant therapy for thin malignant melanoma

G. L. Lewis, S. K. Tyring, Richard Wagner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with thin (less than 0.75 mm) malignant melanoma generally have an excellent prognosis following adequate surgical resection. However, some patients will experience recurrent disease. Once features for a high risk of recurrence in patients with malignant melanoma can be reliably identified, adjuvant intervention will be offered. Two formidable challenges remain before this strategy is adopted: we cannot yet accurately predict the subgroup of patients with thin malignant melanoma who will experience disease progression and an effective, nontoxic adjuvant regimen for this subgroup is not currently available. Future prospects for the adjuvant management of thin malignant melanoma are reviewed.

Original languageEnglish (US)
Pages (from-to)377-379
Number of pages3
JournalCutis
Volume50
Issue number5
StatePublished - 1992

Fingerprint

Melanoma
Therapeutics
Disease Progression
Recurrence

ASJC Scopus subject areas

  • Dermatology
  • Immunology and Allergy

Cite this

Lewis, G. L., Tyring, S. K., & Wagner, R. (1992). Possible role of adjuvant therapy for thin malignant melanoma. Cutis, 50(5), 377-379.

Possible role of adjuvant therapy for thin malignant melanoma. / Lewis, G. L.; Tyring, S. K.; Wagner, Richard.

In: Cutis, Vol. 50, No. 5, 1992, p. 377-379.

Research output: Contribution to journalArticle

Lewis, GL, Tyring, SK & Wagner, R 1992, 'Possible role of adjuvant therapy for thin malignant melanoma', Cutis, vol. 50, no. 5, pp. 377-379.
Lewis, G. L. ; Tyring, S. K. ; Wagner, Richard. / Possible role of adjuvant therapy for thin malignant melanoma. In: Cutis. 1992 ; Vol. 50, No. 5. pp. 377-379.
@article{5a20c8230bc54997834f54e68cb6f260,
title = "Possible role of adjuvant therapy for thin malignant melanoma",
abstract = "Patients with thin (less than 0.75 mm) malignant melanoma generally have an excellent prognosis following adequate surgical resection. However, some patients will experience recurrent disease. Once features for a high risk of recurrence in patients with malignant melanoma can be reliably identified, adjuvant intervention will be offered. Two formidable challenges remain before this strategy is adopted: we cannot yet accurately predict the subgroup of patients with thin malignant melanoma who will experience disease progression and an effective, nontoxic adjuvant regimen for this subgroup is not currently available. Future prospects for the adjuvant management of thin malignant melanoma are reviewed.",
author = "Lewis, {G. L.} and Tyring, {S. K.} and Richard Wagner",
year = "1992",
language = "English (US)",
volume = "50",
pages = "377--379",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "5",

}

TY - JOUR

T1 - Possible role of adjuvant therapy for thin malignant melanoma

AU - Lewis, G. L.

AU - Tyring, S. K.

AU - Wagner, Richard

PY - 1992

Y1 - 1992

N2 - Patients with thin (less than 0.75 mm) malignant melanoma generally have an excellent prognosis following adequate surgical resection. However, some patients will experience recurrent disease. Once features for a high risk of recurrence in patients with malignant melanoma can be reliably identified, adjuvant intervention will be offered. Two formidable challenges remain before this strategy is adopted: we cannot yet accurately predict the subgroup of patients with thin malignant melanoma who will experience disease progression and an effective, nontoxic adjuvant regimen for this subgroup is not currently available. Future prospects for the adjuvant management of thin malignant melanoma are reviewed.

AB - Patients with thin (less than 0.75 mm) malignant melanoma generally have an excellent prognosis following adequate surgical resection. However, some patients will experience recurrent disease. Once features for a high risk of recurrence in patients with malignant melanoma can be reliably identified, adjuvant intervention will be offered. Two formidable challenges remain before this strategy is adopted: we cannot yet accurately predict the subgroup of patients with thin malignant melanoma who will experience disease progression and an effective, nontoxic adjuvant regimen for this subgroup is not currently available. Future prospects for the adjuvant management of thin malignant melanoma are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0026454703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026454703&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 377

EP - 379

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 5

ER -